Loibl Sibylle, von Minckwitz Gunter, Gwyn Karin, Ellis Paul, Blohmer Jens U, Schlegelberger Brigitte, Keller Monika, Harder Sebastian, Theriault Richard L, Crivellari Diana, Klingebiel Thomas, Louwen Frank, Kaufmann Manfred
Department of Obstetrics and Gynaecology, J.W.-Goethe University, Frankfurt am Main, Germany.
Cancer. 2006 Jan 15;106(2):237-46. doi: 10.1002/cncr.21610.
Breast carcinoma during pregnancy (BCP) is a difficult clinical situation, as it appears to put the health of the mother in conflict with that of the fetus.
An international expert meeting was conducted to form guidelines on how to diagnose and treat women with BCP.
The goal for treatment of the pregnant woman with breast carcinoma is the same as that of the nonpregnant breast carcinoma patient: local control of disease and prevention of systemic metastases. However, certain treatment modalities need to be modified because of the potential for adverse effects on the fetus. There is evidence to support the safety of anthracycline-based chemotherapy during the second and third trimesters of pregnancy (Oxford Level of Evidence [LOE] 2b). Because of the lack of evidence, the expert opinion was not to recommend the routine use of newer cytotoxic drugs like the taxanes during pregnancy (LOE 5).
The recommendations provided should help to reach informed decision making by the patient. The ongoing prospective collection of data on BCP, such as that at the University of Texas M.D. Anderson Cancer Center (UTMDACC) and that of the German Breast Group/Breast International Group (GBG/BIG), is necessary to further our knowledge regarding the treatment of this unique group of breast carcinoma patients.
妊娠期乳腺癌（BCP）是一种棘手的临床情况，因为它似乎使母亲的健康与胎儿的健康产生冲突。
召开了一次国际专家会议，以制定关于如何诊断和治疗BCP女性患者的指南。
妊娠期乳腺癌患者的治疗目标与非妊娠期乳腺癌患者相同：局部控制疾病并预防全身转移。然而，由于可能对胎儿产生不良影响，某些治疗方式需要调整。有证据支持在妊娠中期和晚期使用基于蒽环类药物的化疗是安全的（牛津证据水平[LOE]2b）。由于缺乏证据，专家意见不建议在妊娠期常规使用紫杉烷等新型细胞毒性药物（LOE 5）。
提供的这些建议应有助于患者做出明智的决策。持续前瞻性收集关于BCP的数据，如德克萨斯大学MD安德森癌症中心（UTMDACC）以及德国乳腺癌研究组/国际乳腺癌研究组（GBG/BIG）的数据，对于增进我们对这类独特乳腺癌患者治疗的了解是必要的。
